Across treatments, rozanolixizumab and batoclimab were most effective, though rozanolixizumab carried increased risk of adverse events (AEs) and serious AEs. Data from a new analysis of a range of ...
The analysis represents an effort to use bioinformatics to find potential new therapeutic targets for myasthenia gravis (MG). A new genetic analysis of patients with thymoma-associated myasthenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback